Prudential, as an outstanding contract research organization (CRO) in the field of innovative drug and device clinical research and development at home and abroad, has developed into a leader in the industry after 20 years of profound accumulation. We have gathered over 500 professional elites from around the world, with business operations spanning multiple countries and regions such as Asia, Europe, and North America. We are committed to providing excellent, efficient, and comprehensive one-stop services for innovative pharmaceutical and device customers at home and abroad.
With excellent service quality and professional strength, the Prudential brand has won high recognition both domestically and internationally, and has been honored with titles such as "Top 20 Chinese Pharmaceutical Outsourcing Companies", "Best Partner", and "Top 20 Most Investable Companies in China", continuously leading the innovative development of the industry.
Prudential's business scope is extensive, covering multiple fields such as pharmaceuticals, biopharmaceuticals, vaccines, cell/gene therapy, medical devices, traditional Chinese medicine, and natural medicines. We have successfully provided full process services for over 2000 clinical trials for hundreds of large multinational pharmaceutical companies and numerous innovative startups both domestically and internationally. We have participated in the clinical trial design, development, implementation, and registration of numerous innovative drugs and biosimilars, injecting a continuous stream of momentum into the innovation and development of the pharmaceutical industry.
Prudential Pharmaceuticals is highly favored by investors and has completed multiple rounds of financing, attracting funding support from multiple internationally renowned investment institutions. These funds not only provide a solid support for the steady development of the company, but also further consolidate our leading position in the field of pharmaceutical clinical research.
In the future, Prudential will continue to focus on China and rely on an international full-service clinical research and development professional team to work together with all parties to promote the clinical research and development process of innovative drugs and devices. We will strive to build a more sustainable and prosperous industry ecosystem, contributing more to the progress and development of the global pharmaceutical industry.